European Guidelines on Cardiovascular Disease Prevention in Clinical Practice

Backer, Guy De; Амбросиони, Е.; Borch‐Johnsen, Knut; Brotons, Carlos; Cífková, Renata; Dallongeville, Jean; Ebrahim, S.; Færgeman, Ole; Graham, Ian; Mancia, G.; Cats, V. Manger; Orth‐Gomér, Kristina; Perk, Joep; Pyörälà, Kalevi; Rodicio, José L.; Sans, S; Sansoy, Vedat; Sechtem, U; Silber, Sigmund; Thomsen, Troels; Wood, D.

doi:10.20996/1819-6446-2005-1-3-57-65

Cited by 328 publications

(123 citation statements)

References 0 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…Secondary prevention is acknowledged as an effective intervention to reduce levels of CHD 17 . A key component of this approach requires patients to adopt healthy lifestyle habits and cease harmful ones to reduce coronary risk.…”

Section: Lifestyle Changementioning

confidence: 99%

Causal attributions, lifestyle change, and coronary heart disease: Illness beliefs of patients of South Asian and European origin living in the United Kingdom

2008

View full text Add to dashboard Cite

Section: Lifestyle Changementioning

confidence: 99%

Causal attributions, lifestyle change, and coronary heart disease: Illness beliefs of patients of South Asian and European origin living in the United Kingdom

2008

View full text Add to dashboard Cite

“…In patients who unedrgo percutaneous coronary intervention, dual antiplatelet consisting of aspirin and clopidogrel is the regimen of choice to prevent thrombotic complications (De Backer et al, 2003;Gibbons et al, 2003;Patrono et al, 2004) This is the first report of the pharmacokinetics of 600 mg clopidogrel among Jordanians. While native Jordanians are mostly descended from people of villagers and Bedouin descent originating in the Arabian Peninsula (Lowi, 1995), ethnically, the Jordanians represent a mixed stock.…”

Section: Discussionmentioning

confidence: 97%

Pharmacokinetics of 600 mg loading dose of clopidogrel in patients undergoing percutaneous coronary intervention

Yousef¹

2013

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

Clopidogrel is an oral antiplatelet drug. Loading dose of 600 mg clopidogrel was shown to improve clinical outcome in patients following percutaneous coronary intervention (PCI). Wide inter-individual variation has been detected in clopidogrel response that can be related to variation in Clopidogrel serum concentration. The aim of this study was to assess the pharmacokinetics parameters of 600 mg loading dose clopidogrel among Jordanian patients undergoing PCI. Additionally, the development of a simple and a validated High-performance liquid chromatography (HPLC) method for the quantification of clopidogrel carboxylate was described. 80 patients who received a loading of 600 mg Clopidogrel were included in our study, several blood samples were collected at different time points. Validated reverse phase HPLC method was used to determine Clopidogrel carboxylic acid metabolite. Noncompartmental analysis was used to determine peak plasma concentration (C max ), time to peak plasma concentration (T max ), elimination half-life (t 1/2e ), and area under the curve (AUC). The pharmacokineticparameters were characterized by considerable inter-individual differences [C max =24.49±11.64 µg/ml, T max =2.02±1.52 h, AUC 0→∞ = 123.17± 54.6 mg/ml.h, and t1 ⁄ 2e=4.29±2.92 h]. 15% of the patients who had less than one third of the Cmax 8.09±2.34 µg/ml had delayed T max of 4.17±1.76 h, which was not explained by standard in vitro dissolution test. Pharmacokinetic parameters of 600 mg Clopidogrel showed marked inter-individual differences. The low plasma concentrations in some of the patients and the high inter-individual variability may contribute to reported cases of resistance to Clopidogrel therapy. Further studies are needed to explain low C max and delayed T max values in some patients.

show abstract

“…4 This score brings the estimates of cardiovascular mortality, rather than morbidity, applies only for primary prevention (i.e. for non-CHD subjects) and does not include diabetes among its parameters, implying that the presence of diabetes automatically allocates affected subjects into a high-risk group.…”

Section: Estimation Of Cardiovascular Riskmentioning

confidence: 99%

Review article: hyperlipidaemia and cardiovascular risk

Bertolotti

Maurantonio

Gabbi

et al. 2005

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYHyperlipidaemia represents a determinant for the development of atherosclerosis and an important risk factor for cardiovascular disease, particularly in the context of the insulin resistance syndrome. This is characterized by alterations in the profile of plasma lipoprotein including high triglyceride levels, low high-density lipoprotein cholesterol concentrations and the appearance of qualitatively modified, small-dense low-density lipoproteins. Many charts and algorithms have been developed to estimate the entity of coronary and cardiovascular risk as related to dyslipidaemia, on the basis of additional individual risk factors and conditions: most include age and gender, smoking status, hypertension and diabetes. They should preferably be utilized in consistent patient populations, in terms of geographical areas and general risk profile. Pharmacological treatment of dyslipidaemia, in particular with statin drugs, was shown to greatly improve cardiovascular morbidity and mortality. A body of evidence also underlines the need for a multidisciplinary approach, integrating non-pharmacological lifestyle and diet interventions, as well as treatment of concomitant diseases (hypertension and diabetes).

show abstract

European Guidelines on Cardiovascular Disease Prevention in Clinical Practice

Cited by 328 publications

References 0 publications

Causal attributions, lifestyle change, and coronary heart disease: Illness beliefs of patients of South Asian and European origin living in the United Kingdom

Causal attributions, lifestyle change, and coronary heart disease: Illness beliefs of patients of South Asian and European origin living in the United Kingdom

Pharmacokinetics of 600 mg loading dose of clopidogrel in patients undergoing percutaneous coronary intervention

Review article: hyperlipidaemia and cardiovascular risk

Contact Info

Product

Resources

About